MCID: ANG054
MIFTS: 66

Angina Pectoris

Categories: Blood diseases, Cardiovascular diseases, Oral diseases, Rare diseases

Aliases & Classifications for Angina Pectoris

MalaCards integrated aliases for Angina Pectoris:

Name: Angina Pectoris 41 37 17 33
Prinzmetal's Variant Angina 12 75 53 72
Prinzmetal Angina 12 53 15
Variant Angina 12 53 55
Coronary Artery Vasospasm 53 72
Angina Pectoris, Variant 44 72
Prinzmetal's Angina 12 17
Angina Inversa 12 53
Angina 43 63
Variant Angina Pectoris 12
Vasospastic Angina 53

Classifications:



External Ids:

Disease Ontology 12 DOID:0111151
KEGG 37 H01632
MeSH 44 D000788
ICD10 33 I20 I20.1 I20.9
UMLS 72 C0002963 C0010073 C2931193

Summaries for Angina Pectoris

NIH Rare Diseases : 53 Prinzmetal's variant angina (PVA) is characterized by recurrent episodes of chest pain (angina) that usually occur when a person is at rest, between midnight and early morning. "Typical" angina, by contrast, is often triggered by physical exertion or emotional stress. Episodes of PVA can be very painful, and may last from several minutes to thirty minutes. In some cases the pain may spread from the chest to the head, shoulder, or arm. The pain associated with PVA is caused by a spasm in the arteries that supply blood to the heart muscle (coronary arteries). This results in an obstruction of blood flow. In some people, persistent spasms increase the risk for serious complications such as a life-threatening arrhythmia or heart attack. PVA most commonly occurs in people who smoke and people who have high cholesterol or high blood pressure. In many cases it occurs for unknown reasons in otherwise healthy people. In some cases it may be triggered by alcohol withdrawal, stress, exposure to cold, certain medications, or use of stimulants such as cocaine. The diagnosis of PVA involves findings on an electrocardiogram, evidence of the spasms on angiogram, and relief of sudden symptoms with medicines called nitrates. Treatment during an episode to relieve pain and shorten its duration involves sublingual nitroglycerin (a nitrate). Treatment to reduce the frequency of episodes and possibly reduce the risk of serious complications involves calcium channel blockers or long-acting nitrates. For people with PVA who smoke, quitting smoking can lead to a significant decrease in the frequency of episodes. While most people with PVA do not experience serious complications, it is a chronic condition that needs to be monitored over time.

MalaCards based summary : Angina Pectoris, also known as prinzmetal's variant angina, is related to intermediate coronary syndrome and ischemia, and has symptoms including other and unspecified angina pectoris An important gene associated with Angina Pectoris is EDN1 (Endothelin 1), and among its related pathways/superpathways are Dilated cardiomyopathy (DCM) and Fluid shear stress and atherosclerosis. The drugs Glyburide and Amiodarone have been mentioned in the context of this disorder. Affiliated tissues include heart, testes and endothelial, and related phenotypes are cardiovascular system and adipose tissue

Disease Ontology : 12 A coronary artery vasospasm characterized by spasms of the coronary arteries that occur while at rest, generally late at night or early in the morning, resulting in severe chest pain with preserved exercise capacity.

MedlinePlus : 43 Angina is chest pain or discomfort you feel when there is not enough blood flow to your heart muscle. Your heart muscle needs the oxygen that the blood carries. Angina may feel like pressure or a squeezing pain in your chest. It may feel like indigestion. You may also feel pain in your shoulders, arms, neck, jaw, or back. Angina is a symptom of coronary artery disease (CAD), the most common heart disease. CAD happens when a sticky substance called plaque builds up in the arteries that supply blood to the heart, reducing blood flow. There are three types of angina: Stable angina is the most common type. It happens when the heart is working harder than usual. Stable angina has a regular pattern. Rest and medicines usually help. Unstable angina is the most dangerous. It does not follow a pattern and can happen without physical exertion. It does not go away with rest or medicine. It is a sign that you could have a heart attack soon. Variant angina is rare. It happens when you are resting. Medicines can help. Not all chest pain or discomfort is angina. If you have chest pain, you should see your health care provider. NIH: National Heart, Lung, and Blood Institute

KEGG : 37
Angina pectoris is defined as cardiac-induced pain arising from a lack of myocardial oxygen. "Angina" is used to describe clinical symptoms such as discomfort in the chest, jaw, shoulder, back, or arms that are induced by physical exertion or emotional stress and subside with rest or treatment with nitroglycerin. Angina is clinically classified into stable angina (SA) and unstable angina (UA). SA is a chronic medical condition while UA is an acute coronary syndrome. Among the causes of angina pectoris, the most common is coronary artery disease (CAD). At the cellular level, angina pectoris is a result of increased myocardial oxygen demand or decreased myocardial oxygen supply.

PubMed Health : 63 About angina: Angina (an-JI-nuh or AN-juh-nuh) is chest pain or discomfort that occurs if an area of your heart muscle doesn't get enough oxygen-rich blood. Angina may feel like pressure or squeezing in your chest. The pain also can occur in your shoulders, arms, neck, jaw, or back. Angina pain may even feel like indigestion. Angina isn't a disease; it's a symptom of an underlying heart problem. Angina usually is a symptom of coronary heart disease (CHD). CHD is the most common type of heart disease in adults. It occurs if a waxy substance called plaque (plak) builds up on the inner walls of your coronary arteries. These arteries carry oxygen-rich blood to your heart.

Wikipedia : 75 Variant angina, and less commonly vasospastic angina, angina inversa, coronary vessel spasm, or coronary... more...

Related Diseases for Angina Pectoris

Diseases related to Angina Pectoris via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 748)
# Related Disease Score Top Affiliating Genes
1 intermediate coronary syndrome 32.2 TNNI3 PLAT PIK3C2A CRP ACE
2 ischemia 31.2 PLAT NOS3 KNG1 EDN1 ACE
3 coronary artery vasospasm 31.1 PIK3C2A NOS3 EDN1
4 left bundle branch hemiblock 31.1 TNNI3 NPPB ACE
5 cardiogenic shock 31.0 PLAT PIK3C2A NPPB
6 heart valve disease 31.0 NPPB CRP ACE
7 dressler's syndrome 31.0 PLAT CRP
8 aortic valve insufficiency 31.0 NPPB ACE
9 peripheral artery disease 30.9 NOS3 CRP ACE
10 cardiac arrest 30.9 PIK3C2A NPPB ACE
11 lipid metabolism disorder 30.9 LPA CRP APOA1 ACE
12 atherosclerosis susceptibility 30.8 NOS3 LPA CRP APOA1
13 aortic valve disease 2 30.8 NPPB CRP ACE
14 cardiac rupture 30.8 PLAT CRP
15 anterolateral myocardial infarction 30.7 PLAT NPPB ACE
16 myocardial stunning 30.7 TNNI3 EDN1
17 cerebral atherosclerosis 30.7 APOA1 ACE
18 cerebrovascular disease 30.7 PLAT CRP APOA1 ACE
19 arteriosclerosis 30.7 LPA EDN1 CRP APOA1 ACE
20 eisenmenger syndrome 30.6 PLAT EDN1
21 congestive heart failure 30.6 NPPB KNG1 EDN1 ADRB1 ACE
22 peripheral vascular disease 30.6 PLAT LPA CRP APOA1 ACE
23 impotence 30.5 NOS3 KNG1 EDN1
24 gas gangrene 30.5 TNNI3 PIK3C2A
25 coronary stenosis 30.4 TNNI3 PIK3C2A NPPB CRP APOA1 ACE
26 respiratory failure 30.4 PIK3C2A CRP ACE
27 generalized atherosclerosis 30.4 CRP ACE
28 inferior myocardial infarction 30.4 PLAT PIK3C2A NPPB
29 pericardial effusion 30.4 PIK3C2A NPPB CRP
30 atrial standstill 1 30.4 TNNI3 NPPB ADRB1 ACE
31 pulmonary embolism 30.3 TNNI3 PLAT NPPB CRP
32 sexual disorder 30.3 NOS3 EDN1 ACE
33 renovascular hypertension 30.3 NOS3 EDN1 ACE
34 diastolic heart failure 30.2 NPPB NOS3 ACE
35 orthostatic intolerance 30.2 NOS3 EDN1 ADRB1
36 posterior myocardial infarction 30.1 PLAT PIK3C2A
37 renal artery disease 30.1 NOS3 ACE
38 systemic scleroderma 30.0 EDN1 CRP ACE
39 endocarditis 29.9 TNNI3 PLAT PIK3C2A CRP
40 systolic heart failure 29.8 NPPB EDN1 CRP ADRB1 ACE
41 aortic coarctation 29.8 NOS3 EDN1 ADRB1 ACE
42 atrial fibrillation 29.8 PLAT NPPB CRP ADRB1 ACE
43 aortic valve disease 1 29.7 TNNI3 NPPB LPA CRP ACE
44 lemierre's syndrome 29.6 KNG1 CRP
45 renal hypertension 29.6 NPPB KNG1 EDN1 ACE
46 tetralogy of fallot 29.6 NPPB EDN1 CRP
47 sleep apnea 29.5 NPPB NOS3 EDN1 CRP ACE
48 stroke, ischemic 29.5 PLAT NOS3 LPA CRP ACE
49 kidney disease 29.4 NPPB NOS3 LPA EDN1 CRP ACE
50 vascular disease 29.2 PLAT NOS3 LPA KNG1 EDN1 CRP

Comorbidity relations with Angina Pectoris via Phenotypic Disease Network (PDN):


Esophagitis Hypertension, Essential
Intermediate Coronary Syndrome Mitral Valve Disease

Graphical network of the top 20 diseases related to Angina Pectoris:



Diseases related to Angina Pectoris

Symptoms & Phenotypes for Angina Pectoris

UMLS symptoms related to Angina Pectoris:


angina pectoris, other and unspecified angina pectoris

MGI Mouse Phenotypes related to Angina Pectoris:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 cardiovascular system MP:0005385 9.96 ACE ADRB1 APOA1 CRP EDN1 HTR1B
2 adipose tissue MP:0005375 9.72 ACE ADRB1 HTR1B NOS3 PIK3C2A
3 endocrine/exocrine gland MP:0005379 9.7 ACE ADRB1 APOA1 EDN1 HTR1B NOS3
4 growth/size/body region MP:0005378 9.61 ACE ADRB1 APOA2 EDN1 HTR1B KNG1
5 muscle MP:0005369 9.1 ADRB1 EDN1 HTR1B NOS3 PLAT TNNI3

Drugs & Therapeutics for Angina Pectoris

PubMed Health treatment related to Angina Pectoris: 63

Treatments for angina include lifestyle changes, medicines, medical procedures, cardiac rehabilitation (rehab), and other therapies. The main goals of treatment are to: Reduce pain and discomfort and how often it occursPrevent or lower your risk for heart attack and death by treating your underlying heart condition Lifestyle changes and medicines may be the only treatments needed if your symptoms are mild and aren't getting worse. If lifestyle changes and medicines don't control angina, you may need medical procedures or cardiac rehab. Unstable angina is an emergency condition that requires treatment in a hospital.

Drugs for Angina Pectoris (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 588)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Glyburide Approved Phase 4 10238-21-8 3488
2
Amiodarone Approved, Investigational Phase 4 1951-25-3 2157
3
Trimetazidine Approved, Investigational Phase 4 5011-34-7
4
Telmisartan Approved, Investigational Phase 4 144701-48-4 65999
5
Acarbose Approved, Investigational Phase 4 56180-94-0 441184
6
Eptifibatide Approved, Investigational Phase 4 188627-80-7 123610
7
Udenafil Approved, Investigational Phase 4 268203-93-6 6918523
8
Thrombin Approved, Investigational Phase 4
9
Pantoprazole Approved Phase 4 102625-70-7 4679
10
Glimepiride Approved Phase 4 93479-97-1 3476
11
Sevoflurane Approved, Vet_approved Phase 4 28523-86-6 5206
12
Spironolactone Approved Phase 4 1952-01-7, 52-01-7 5833
13
Cilostazol Approved, Investigational Phase 4 73963-72-1 2754
14
Simvastatin Approved Phase 4 79902-63-9 54454
15
Aspirin Approved, Vet_approved Phase 4 50-78-2 2244
16
Morphine Approved, Investigational Phase 4 57-27-2 5288826
17
Naloxone Approved, Vet_approved Phase 4 465-65-6 5284596
18
Metoclopramide Approved, Investigational Phase 4 364-62-5 4168
19
Glucagon Approved Phase 4 16941-32-5
20
Pravastatin Approved Phase 4 81093-37-0 54687
21
Molsidomine Approved, Investigational Phase 4 25717-80-0
22
Bivalirudin Approved, Investigational Phase 4 128270-60-0 16129704
23
Fenofibrate Approved Phase 4 49562-28-9 3339
24
Nicotinamide Approved, Investigational Phase 4 98-92-0 936
25
Erythromycin Approved, Investigational, Vet_approved Phase 4 114-07-8 441411 12560
26
Zinc Approved, Investigational Phase 4 7440-66-6 32051
27
Liraglutide Approved Phase 4 204656-20-2 44147092
28
Bupropion Approved Phase 4 34841-39-9, 34911-55-2 444
29
Pioglitazone Approved, Investigational Phase 4 111025-46-8 4829
30
Digoxin Approved Phase 4 20830-75-5 30322 2724385
31
Olmesartan Approved, Investigational Phase 4 144689-63-4, 144689-24-7 130881 158781
32
Insulin glargine Approved Phase 4 160337-95-1
33
Felodipine Approved, Investigational Phase 4 72509-76-3 3333
34
Cefpirome Approved Phase 4 84957-29-9 5479539
35
Moxifloxacin Approved, Investigational Phase 4 354812-41-2, 151096-09-2 152946
36
Norgestimate Approved, Investigational Phase 4 35189-28-7 6540478
37
Ethinyl Estradiol Approved Phase 4 57-63-6 5991
38
Cangrelor Approved Phase 4 163706-06-7 9854012
39
Fondaparinux Approved, Investigational Phase 4 104993-28-4
40
Tamsulosin Approved, Investigational Phase 4 106133-20-4 129211
41
Quinapril Approved, Investigational Phase 4 85441-61-8 54892
42
Eplerenone Approved Phase 4 107724-20-9 150310 443872
43
Bezafibrate Approved, Investigational Phase 4 41859-67-0 39042
44
Tranylcypromine Approved, Investigational Phase 4 155-09-9 441233
45
Nimodipine Approved, Investigational Phase 4 66085-59-4 4497
46 Coconut Approved Phase 4
47
Peppermint Approved Phase 4
48
Peppermint oil Approved, Investigational Phase 4 8006-90-4
49
Desflurane Approved Phase 4 57041-67-5 42113
50
Propofol Approved, Investigational, Vet_approved Phase 4 2078-54-8 4943

Interventional clinical trials:

(show top 50) (show all 1671)
# Name Status NCT ID Phase Drugs
1 Efficacy Study of Atorvastatin to Treat Variant Angina Unknown status NCT00620204 Phase 4 atorvastatin
2 A Randomized, Double-blind, Placebo-controlled Trial of Dan-shen Extract in Patients With Stable Angina Pectoris Unknown status NCT02870764 Phase 4 Dan-shen extract;Placebo
3 Impact of Paclitaxel-eluting Stent for Small Coronary Artery Disease Unknown status NCT00955214 Phase 4
4 Efficacy and Safety of Salvianolate Injection in Elderly Patients With Unstable Angina Pectoris: a Parallel, Double Blind, Randomized, Controlled, Multi-center Trial. Unknown status NCT03037047 Phase 4 0.9% Sodium Chloride Injection;salvianolate injection
5 Coronary Angioplasty in Octogenarians With Emergent Coronary Syndromes: The Octogenarians Study Unknown status NCT02126202 Phase 4
6 Randomized Study on SCS for the Treatment of Refractory Angina Pectoris Unknown status NCT00121654 Phase 4
7 The Effects of Pravastatin and Rosuvastatin on the Tissue Characteristics and Morphology of Coronary Plaques in Patients With Stable Angina Pectoris Unknown status NCT01325818 Phase 4 pravastatin, rosuvastatin
8 Effect of Ticagrelor on Adenosine-Induced Coronary Flow Reserve in Patients With Microvascular Angina Unknown status NCT02284048 Phase 4 ticagrelor
9 The Effect of Testosterone Therapy on Angina Threshold and Atheroma in Patients With Chronic Stable Angina Unknown status NCT00131183 Phase 4 Nebido
10 Safety of Amiodarone and Ranolazine Together in Patients With Stable Angina Unknown status NCT01558830 Phase 4 ranolazine;placebo
11 Effect of Vitamin C Infusion on Coronary Reperfusion Indexes Unknown status NCT01090895 Phase 4 Vitamin C;Placebo
12 Effect of Ranolazine on Activity Level in Patients With Angina After FFR Based Deferred Intervention Unknown status NCT03044964 Phase 4 Ranolazine;Placebo
13 Efficacy and Safety Study of Guanxin Shutong Capsule to Treat Chronic Stable Angina: A Randomised, Double-blind, Placebo-controlled Clinical Trial Unknown status NCT02280850 Phase 4 Guanxin Shutong Capsule;Placebo Capsule;nitroglycerine
14 Comparison of Low-dose Heparin Versus Standard Dose Heparin During Coronary Interventions (DEDICA Trial) Unknown status NCT01694459 Phase 4 Low-dose heparin;Standard dose heparin
15 Multicenter Trial on Clinical Utility of Acarbose in Patients With Ischemic Heart Disease Accompanied by Abnormal Glucose Regulation Unknown status NCT00858676 Phase 4 acarbose
16 Clinical Study of Combination Therapy for Angina of Coronary Heart Disease With Aspirin and Salvianolate Injection Based on Population Pharmacokinetics and Therapeutic Effect:A Randomized, Controlled Trial Unknown status NCT02694848 Phase 4 Salvianolate injection;Aspirin
17 Prospective Randomised Study Comparing Efficacy of Treatment Coronary In-stent Restenosis Using Drug Eluting Paclitaxel-coated Balloon and Drug Eluting Stent With Everolimus. Unknown status NCT01735825 Phase 4
18 Open-label Clinical Pharmacokinetic Study of Cardionat®, Capsules 250 mg (JSC Nizhpharm, Russia) Using in Health Athlete Volunteers Unknown status NCT02758912 Phase 4 оral intake of study drug capsules; study drug - Cardionat ® (trimethylhydrazinium propionate dihydrate), oral capsules 250 mg
19 A Comparative Study to Assess the Efficacy of Nicorandil+Atenolol vs Atenolol in Treatment naïve Patients of Chronic Stable Angina. Unknown status NCT01397994 Phase 4 Nicorandil;Atenolol
20 Bedside Testing of the CYP2C19 Gene to Asses Effectiveness of Clopidogrel in Coronary Artery Disease Patients Treated With Percutaneous Coronary Intervention : Individualized Antiplatelet Drugs Treatment to Improve Prognosis Unknown status NCT01823185 Phase 4 clopidogrel;Ticagrelor or prasugrel
21 Comparative Study of the Effects of Telmisartan and Nebivolol on 24-h Ambulatory Blood Pressure and Arterial Stiffness in Patients With Arterial Hypertension Unknown status NCT02057328 Phase 4 TELMISARTAN;NEBIVOLOL
22 the Effect of Nifedipine Controlled Release Tablets in Hypertensive Patients on Chronic Maintenance Hemodialysis and the Influence of Hemodialysis on the Plasma Concentration of Nifedipine Unknown status NCT01021501 Phase 4 nifedipine controlled release tablets
23 Evaluation of Radial Strain Versus Fractional Shortening and Fractional Area Change for Assessment of Left Ventricular Function in Transesophageal Echocardiography Unknown status NCT01080495 Phase 4
24 Comparison of Vascular Remodeling Between Different Antianginal Medication Evaluated by Noninvasive ECG-gated Fundus Photographic Evaluation Unknown status NCT01162902 Phase 4 Diltiazem treated group;Bisoprolol treated group;Candesartan treated group
25 A Comparative Evaluation of Efficacy and Safety in the 3-Months DAPT Group vs. the 6-Months DAPT Group of Patients Treated With the Coroflex ISAR Stent; A Prospective, Multicenter, Randomized, Open-Label Clinical Trial Unknown status NCT02609698 Phase 4 3 months DAPT;6 months DAPT
26 Pharmacokinetics and Pharmacodynamics of Ticagrelor in Patients With Stable Angina, NSTEMI and STEMI Undergoing PCI Unknown status NCT02012140 Phase 4 ticagrelor
27 Understanding of Chest Pain in Microvascular Disease Proved by Cardiac Magnetic Resonance Image Unknown status NCT01769482 Phase 4 Udenafil;placebo
28 The Safety and Efficacy of Intensive Statin Therapy in PCI Patient With Acute Coronary Syndrome Unknown status NCT01372839 Phase 4 Atorvastatin;Statin
29 A Pilot Study Exploring Efficacy and Safety of Amlodipine in the Stented Angina Patients Unknown status NCT01120327 Phase 4 Placebo;Amlodipine
30 Efficacy and Safety of New Generation Drug Eluting Stents Associated With an Ultra Short Duration of Dual Antiplatelet Therapy. Design of the Short Duration of Dual antiplatElet Therapy With SyNergy II Stent in Patients Older Than 75 Years Undergoing Percutaneous Coronary Revascularization. Unknown status NCT02099617 Phase 4
31 Efficacy Study of Nicorandil on Neointima After Coronary Drug-eluting Stent Implantation in Patients With Diabetic Mellitus Unknown status NCT02328521 Phase 4 Nicorandil;nicorandil placebo
32 A Morbi-Mortality and Remodeling Study With Valsartan in Patients With Hypertension and Cardiovascular Disease Unknown status NCT00133328 Phase 4 valsartan
33 Ranolazine for the Treatment of sYmPtoms of PaLpitations in patiEnts With Ischemic Heart Disease - The RYPPLE Trial Unknown status NCT01495520 Phase 4 Ranolazine;Placebo
34 Effects of Sodium Tanshinone IIA Sulfonate on Left Ventricular Remodeling in Patients With ST-segment Elevation Myocardial Infarction Following Percutaneous Coronary Intervention Unknown status NCT02524964 Phase 4 sodium tanshinone IIA sulfonate
35 The Randomly Controlled Clinical Trial of the Association Between Very Small Embryonic-like Stem Cells and the Prognosis of Coronary Artery Disease Patients Unknown status NCT01633359 Phase 4 Intensive statin;Routine statin
36 Ischemia In Hemodialysed Patients And Outcome: Ivabradine Versus Carvedilol. A Randomized, Double Blind Study Unknown status NCT01425164 Phase 4 Ivabradine;Carvedilol
37 TWice overnIght High-dose ranoLazIne Pretreatment for preventinG Myocardial iscHemic Damage in Patients With Stable Angina Undergoing percuTaneous Coronary Intervention Unknown status NCT01491061 Phase 4 Ranolazine;Placebo
38 A Prospective Multicenter Trial Evaluating Helios Biodegradable Polymer Sirolimus-eluting Stent Safety and Effectiveness in Treatment of Coronary Artery Disease Unknown status NCT01880879 Phase 4
39 Ranolazine, Ethnicity and the Metabolic Syndrome - REMS Study Unknown status NCT01304095 Phase 4 Ranolazine
40 Impairment of Gastric Emptying During Acute Phase of Myocardial Infarction. Impact on Oral Antiplatelet Treatment Efficacy. The GASTRIM Study. Unknown status NCT02251249 Phase 4 Paracetamol concentration time curve from 0 to 120 min
41 Impact of Stent Platform on Shear Stress Distribution and Subsequent Vessel Healing After Drug-eluting Stent Implantation (SHEAR DES) Unknown status NCT01942044 Phase 4
42 A Randomized, Double-blind, Multi-centered, Placebo-controlled Trial to Examine Effects of Heart-protecting Musk Pill on Clinical Outcome in Patients With Chronic Stable Coronary Artery Disease Unknown status NCT01897805 Phase 4 Heart-protecting Musk Pill;Placebo
43 A Double-Blind, Placebo-Controlled Study of Escitalopram in the Prevention of Depression in Patients With Acute Coronary Syndrome Unknown status NCT00140257 Phase 4 Escitalopram
44 Single-center Randomized Controlled Study of Omeprazole and Pantoprazole Antiplatelet Effect of Clopidogrel Clinical Randomized Controlled Trials Unknown status NCT01735227 Phase 4 omeprazole;Pantoprazole
45 Assessment of Coronary Flow Reserve by Doppler Flow WIre in Patients With Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention: Differences Between the Loading Dose of Prasugrel and Ticagrelor . Unknown status NCT02032303 Phase 4 Ticagrelor loading;Prasugrel loading
46 Sleep Disordered Breathing in TIA/Ischemic Stroke: Effects on Short- and Long-term Outcome and CPAP Treatment Efficacy: an Open, Observational, Clinical, Multicentre Trial With a Randomized Arm Unknown status NCT01097967 Phase 4
47 Randomised, Double-blind, Placebo-controlled Trial of IVabradine in Patients With Acute Coronary Syndrome: Effects of the If Current Inhibitor Ivabradine or rEduction of Inflammation maRkers in Patients With Acute Coronary Syndrome Unknown status NCT00815100 Phase 4 Ivabradine;Placebo
48 A Comparison of Myocardial Protection Using Preconditioning With Sevoflurane Against High Thoracic Epidural Analgesia for CABG Surgery Unknown status NCT00244283 Phase 4 Sevoflurane
49 Minimizing Post-Procedural Vascular Complications: Comparing Bivalirudin Versus Heparin/GP IIB/IIA in Patients Undergoing Percutaneous Coronary Intervention Unknown status NCT00476944 Phase 4
50 Assessment of Coronary Flow Reserve by Doppler Flow Wire in Patients With Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention Differences Between the Loading Dose of Ticagrelor and Clopidogrel Unknown status NCT02032290 Phase 4 ticagrelor loading;Clopidogrel loading

Search NIH Clinical Center for Angina Pectoris

Inferred drug relations via UMLS 72 / NDF-RT 51 :


Acebutolol
Amlodipine
Amlodipine
Amlodipine Besylate
Atenolol
Atorvastatin
Bisoprolol
Carvedilol
Diltiazem
Diltiazem
Diltiazem Hydrochloride
Diltiazem maleate
DITIAZ
Ergometrine
Felodipine
Isosorbide dinitrate
Isosorbide mononitrate
Isradipine
Labetalol
Metoprolol
Nadolol
Nicardipine
Nicardipine
Nicardipine hydrochloride
Nifedipine
Nifedipine
Nisoldipine
Nitroglycerin
Pindolol
Propranolol
Valproate bismuth
Verapamil
Verapamil
Verapamil hydrochloride

Cochrane evidence based reviews: angina pectoris, variant

Genetic Tests for Angina Pectoris

Anatomical Context for Angina Pectoris

MalaCards organs/tissues related to Angina Pectoris:

41
Heart, Testes, Endothelial, Spinal Cord, Lung, Bone, Kidney

Publications for Angina Pectoris

Articles related to Angina Pectoris:

(show top 50) (show all 19012)
# Title Authors PMID Year
1
Efficacy and safety of Xinnaoning capsule in treating chronic stable angina (qi stagnation and blood stasis syndrome): Study protocol for a multicenter, randomized, double-blind, placebo-controlled trial. 38 17
31374015 2019
2
Comparative efficacy of Chinese herbal injections for angina pectoris: A Bayesian network meta-analysis of randomized controlled trials. 38 17
30935533 2019
3
Magnetic Resonance Perfusion or Fractional Flow Reserve in Coronary Disease. 17
31216398 2019
4
Endothelial nitric oxide synthase T-786C mutation, a reversible etiology of Prinzmetal's angina pectoris. 9 38
20211321 2010
5
Somatic health in the Indigenous Sami population - a systematic review. 38
31262241 2019
6
Cannabis use and acute coronary syndrome. 38
30964363 2019
7
Arcuate artery calcification on transvaginal sonography may predict coronary artery heart disease. 38
31274364 2019
8
Serum malondialdehyde-modified low-density lipoprotein levels on admission predict prognosis in patients with acute coronary syndrome undergoing percutaneous coronary intervention. 38
30898480 2019
9
Effects of Exercise Training With and Without Ranolazine on Peak Oxygen Consumption, Daily Physical Activity, and Quality of Life in Patients With Chronic Stable Angina Pectoris. 38
31296368 2019
10
Impact of the preprocedural nutrition status on the clinical outcomes of patients after pacemaker implantation for bradycardia. 38
30879918 2019
11
Value of the expression of miR-208, miR-494, miR-499 and miR-1303 in early diagnosis of acute myocardial infarction. 38
31176780 2019
12
The impact of coronary sinus narrowing on diastolic function in patients with refractory angina. 38
30979603 2019
13
Pro-inflammatory biomarkers in women with non-obstructive angina pectoris and coronary microvascular dysfunction. 38
31193994 2019
14
Tanshinol borneol ester, a novel synthetic small molecule angiogenesis stimulator inspired by botanical formulations for angina pectoris. 38
31116880 2019
15
Activation of cardiac AMPK-FGF21 feed-forward loop in acute myocardial infarction: Role of adrenergic overdrive and lipolysis byproducts. 38
31413360 2019
16
Risk of comorbid cardiovascular disease in Korean long-term cancer survivors. 38
31433537 2019
17
Cerebral Perfusion and the Occurrence of Nonfocal Transient Neurological Attacks. 38
31422397 2019
18
Carotid Endarterectomy in a Patient With Type 2 Myocardial Infarction During Preparation for Surgery: A Case Report. 38
30985316 2019
19
Structural Basis for Diltiazem Block of a Voltage-gated Ca2+ Channel. 38
31391290 2019
20
Intravascular Polarimetry in Patients With Coronary Artery Disease. 38
31422135 2019
21
Risk factors for coronary artery disease in young patients with stable angina pectoris 38
31385674 2019
22
Usefulness of the CHA2DS2-VASc Score to Predict Adverse Outcomes in Acute Coronary Syndrome Patients Without Atrial Fibrillation Undergoing Percutaneous Coronary Intervention. 38
31235063 2019
23
Common Causes of Pain in Systemic Sclerosis: Frequency, Severity, and Relationship to Disease Status, Depression, and Quality of Life. 38
31103501 2019
24
Association between cerebral microbleeds and hypertension in the Swedish general population "Good Aging in Skåne" study. 38
31274244 2019
25
NLRP3 inflammasome expression in peripheral blood monocytes of coronary heart disease patients and its modulation by rosuvastatin. 38
31257469 2019
26
Adjuvant treatment of coronary heart disease angina pectoris with Chinese patent medicine: A prospective clinical cohort study. 38
31415432 2019
27
Food insecurity, acculturation and diagnosis of CHD and related health outcomes among immigrant adults in the USA. 38
31405405 2019
28
Relationships Among Self-Reported Hearing Problems, Psychological Distress, and Cardiovascular Disease in U.S. Adults, National Health Interview Survey 1997-2017. 38
31339788 2019
29
Prediction of Coronary Revascularization in Stable Angina: Comparison of FFRCT With CMR Stress Perfusion Imaging. 38
31422146 2019
30
Normal values of aortic dimensions assessed by multidetector computed tomography in the Copenhagen General Population Study. 38
30809640 2019
31
Polyunsaturated Fatty Acid Impact on Clinical Outcomes in Acute Coronary Syndrome Patients With Dyslipidemia: Subanalysis of HIJ-PROPER. 38
31390907 2019
32
Is quality of life impairment associated with chronic diseases dependent on educational level? 38
30668855 2019
33
Cardioprotective mechanism study of salvianic acid A sodium based on a proteome microarray approach and metabolomic profiling of rat serum after myocardial infarction. 38
31099812 2019
34
The effectiveness of moxibustion for stable angina pectoris: A meta-analysis and trial sequential analysis protocol. 38
31415403 2019
35
Corn silk decoction for blood lipid in patients with angina pectoris: A systematic review and meta-analysis. 38
31423665 2019
36
The impact of the coronary sinus reducer upon left ventricular function in patients with refractory angina pectoris. 38
31373415 2019
37
Expression profiles and potential functions of long non-coding RNA in stable angina pectoris patients from Uyghur population of China. 38
31413167 2019
38
Procedural findings and early healing response after implantation of a self-apposing bioresorbable scaffold in coronary bifurcation lesions. 38
31053981 2019
39
Differential value of eosinophil count in acute coronary syndrome among elderly patients. 38
31347431 2019
40
Tissue characteristics of culprit lesion and myocardial tissue-level perfusion in non-ST-segment elevation acute coronary syndromes: The EARLY-MYO-ACS study. 38
30772013 2019
41
Lipid-Lowering Prescription Patterns in Patients With Diabetes Mellitus or Cardiovascular Disease. 38
31362878 2019
42
Occult cardiac amyloidosis: the last chapter of a 2-year long story. 38
31368039 2019
43
Hypertension and cardiovascular diseases in Swedish persons with haemophilia - A longitudinal registry study. 38
31386935 2019
44
The Mexican consensus on non-cardiac chest pain. 38
31213326 2019
45
Which comorbidity classification is best suited to identify patients at risk for 90-day and long-term non-bladder cancer mortality after radical cystectomy? 38
31267181 2019
46
Kounis Syndrome—not a Single-organ Arterial Disorder but a Multisystem and Multidisciplinary Disease 38
31198019 2019
47
Interleukin-32 increases in coronary arteries and plasma from patients with coronary artery disease. 38
31326419 2019
48
Plasma soluble C-type lectin-like receptor-2 is associated with the risk of coronary artery disease. 38
31280468 2019
49
Myocardial first pass perfusion assessed by cardiac magnetic resonance and coronary microvascular dysfunction in women with angina and no obstructive coronary artery disease. 38
30889989 2019
50
Effect and Safety of Guanxinning Tablet () for Stable Angina Pectoris Patients with Xin (Heart)-Blood Stagnation Syndrome: A Randomized, Multicenter, Placebo-Controlled Trial. 38
31302851 2019

Variations for Angina Pectoris

Expression for Angina Pectoris

LifeMap Discovery
Genes differentially expressed in tissues of Angina Pectoris patients vs. healthy controls: 35
# Gene Description Tissue Up/Dn Fold Change (log2) P value
1 EGR3 early growth response 3 Blood + 4.04 0.001
Search GEO for disease gene expression data for Angina Pectoris.

Pathways for Angina Pectoris

GO Terms for Angina Pectoris

Cellular components related to Angina Pectoris according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular space GO:0005615 9.56 PLAT NPPB KNG1 EDN1 CRP APOA2
2 blood microparticle GO:0072562 9.54 KNG1 APOA2 APOA1
3 high-density lipoprotein particle GO:0034364 9.4 APOA2 APOA1
4 very-low-density lipoprotein particle GO:0034361 9.32 APOA2 APOA1
5 extracellular region GO:0005576 9.28 PLAT NPPB LPA KNG1 EDN1 CRP
6 chylomicron GO:0042627 9.26 APOA2 APOA1
7 spherical high-density lipoprotein particle GO:0034366 9.16 APOA2 APOA1

Biological processes related to Angina Pectoris according to GeneCards Suite gene sharing:

(show all 36)
# Name GO ID Score Top Affiliating Genes
1 response to drug GO:0042493 9.87 HTR1B EDN1 APOA2 APOA1
2 lipid transport GO:0006869 9.81 LPA APOA2 APOA1
3 phosphatidylcholine biosynthetic process GO:0006656 9.67 APOA2 APOA1
4 protein kinase C-activating G protein-coupled receptor signaling pathway GO:0007205 9.67 HTR1B EDN1
5 cholesterol transport GO:0030301 9.66 APOA2 APOA1
6 negative regulation of proteolysis GO:0045861 9.66 PLAT KNG1
7 lipoprotein metabolic process GO:0042157 9.65 APOA2 APOA1
8 cholesterol efflux GO:0033344 9.65 APOA2 APOA1
9 regulation of vasoconstriction GO:0019229 9.65 EDN1 ACE
10 vasodilation GO:0042311 9.64 NOS3 KNG1
11 reverse cholesterol transport GO:0043691 9.63 APOA2 APOA1
12 vasoconstriction GO:0042310 9.63 HTR1B EDN1
13 high-density lipoprotein particle remodeling GO:0034375 9.62 APOA2 APOA1
14 negative regulation of blood coagulation GO:0030195 9.62 KNG1 EDN1
15 heart contraction GO:0060047 9.61 TNNI3 ACE
16 regulation of blood vessel diameter GO:0097746 9.61 NPPB ACE
17 positive regulation of urine volume GO:0035810 9.6 NPPB EDN1
18 positive regulation of renal sodium excretion GO:0035815 9.59 NPPB EDN1
19 low-density lipoprotein particle remodeling GO:0034374 9.58 LPA APOA2
20 high-density lipoprotein particle assembly GO:0034380 9.58 APOA2 APOA1
21 phospholipid efflux GO:0033700 9.56 APOA2 APOA1
22 high-density lipoprotein particle clearance GO:0034384 9.55 APOA2 APOA1
23 chylomicron assembly GO:0034378 9.54 APOA2 APOA1
24 positive regulation of cholesterol esterification GO:0010873 9.52 APOA2 APOA1
25 body fluid secretion GO:0007589 9.51 NPPB EDN1
26 chylomicron remodeling GO:0034371 9.49 APOA2 APOA1
27 negative regulation of hydrolase activity GO:0051346 9.48 NOS3 APOA1
28 regulation of systemic arterial blood pressure by endothelin GO:0003100 9.46 NOS3 EDN1
29 peptidyl-methionine modification GO:0018206 9.43 APOA2 APOA1
30 negative regulation of cytokine secretion involved in immune response GO:0002740 9.4 APOA2 APOA1
31 regulation of intestinal cholesterol absorption GO:0030300 9.37 APOA2 APOA1
32 protein oxidation GO:0018158 9.32 APOA2 APOA1
33 negative regulation of lipase activity GO:0060192 9.26 APOA2 APOA1
34 regulation of blood pressure GO:0008217 9.26 NPPB NOS3 EDN1 ACE
35 negative regulation of very-low-density lipoprotein particle remodeling GO:0010903 9.16 APOA2 APOA1
36 regulation of blood vessel size GO:0050880 8.92 NPPB NOS3 KNG1 EDN1

Molecular functions related to Angina Pectoris according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 signaling receptor binding GO:0005102 9.71 PLAT NPPB KNG1 EDN1
2 cholesterol transporter activity GO:0017127 9.37 APOA2 APOA1
3 high-density lipoprotein particle binding GO:0008035 9.32 APOA2 APOA1
4 phosphatidylcholine-sterol O-acyltransferase activator activity GO:0060228 9.26 APOA2 APOA1
5 lipase inhibitor activity GO:0055102 9.16 APOA2 APOA1
6 high-density lipoprotein particle receptor binding GO:0070653 8.96 APOA2 APOA1
7 apolipoprotein receptor binding GO:0034190 8.62 APOA2 APOA1

Sources for Angina Pectoris

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 TGDB
71 Tocris
72 UMLS
73 UMLS via Orphanet
Content
Loading form....